HLA Typing Laboratory Financial Model

Description

The financial model is built for a specialized immunogenetics laboratory providing high-resolution HLA typing via Next-Generation Sequencing (NGS). The model reflects the real-life logic of a lab that processes batches of samples on expensive sequencers, where throughput and cost per sample critically depend on batch size and panel configuration. It addresses the inherent complexity of running a high-throughput diagnostic lab with multi-gene panels, variable turnaround times, and stringent quality requirements.

It captures the full investment cycle: from ordering capital equipment (sequencer, liquid handler, bioinformatics infrastructure) and building a clean-room facility to completing laboratory accreditation and validation stages required before first revenue. The timeline accounts for the delay between equipment installation and operational readiness due to staff hiring, training, and quality management system implementation. While the model provides a robust order-of-magnitude estimate of total capital requirements, actual values will depend on specific equipment choices and local regulations.

Revenue modeling includes per-sample typing fees across multiple HLA loci, full gene panels with distinct pricing, and optional contract research services. Operating expenses differentiate between fixed costs (technical staff, facility, equipment service contracts typically 8–12% of equipment cost) and variable costs driven by sample volume (reagents, disposables, bioinformatics software per-sample cost). The model auto-calculates batching efficiency, showing how sample volume impacts cost per test and helping optimize run scheduling for profitability.

Modeling specifics

• Batch processing logic: models sample runs on sequencers with variable batch sizes, dynamically allocating reagent consumption and equipment time – directly links lab throughput to cost per test.
• Equipment leasing vs purchase comparison with integrated maintenance contract modeling (annual service cost as a percentage of capital cost), enabling informed financing decisions.
• Accreditation timeline simulation: a dedicated pre-revenue phase with monthly milestones for proficiency testing, validation panels, SOP documentation, and staffing ramp-up, delaying revenue start accordingly.
• Multi-product revenue structure: supports multiple HLA panels (e.g., A/B/C/DR/DQ, high-resolution, disease-specific) with unique pricing, reagent consumption, and turnaround time settings.
• Reagent lot and inventory dynamics: minimum order quantities, reagent shelf-life, and wasted unused kits are modeled to prevent underestimation of consumable costs during low-volume periods.
• Staff ramp-up schedule: phased hiring of geneticists, technicians, and bioinformaticians aligned with accreditation stages, with associated training costs and productivity ramp curves.
• Cash flow impact of batching: revenue is recognized upon case delivery, not when samples are received, revealing working capital needs from batch accumulation to report sign-out.

What's included in the base version

• Capital expenditure schedule with equipment list, leasing options, and facility setup costs
• FTE staffing plan with salary, benefits, and hiring ramp-up linked to accreditation milestones
• Sample batching & panel configuration module with reagent consumption per run
• Reagent procurement model with lot sizing, safety stock, and expiration logic
• Accreditation timeline and pre-operational expense block
• Multi-stream revenue model by test type, panel, and volume
• Full financial statements: 5-year P&L, cash flow, balance sheet
• Key investment metrics: IRR, NPV, payback period, and break-even analysis
• Sensitivity tables on sample volume, batch size, price per test, and reagent cost

Common modeling mistakes

• Assuming uniform monthly sample flow without batching constraints – overestimates revenue by 15–25% and underestimates reagent cost per test because idle capacity and partial runs are ignored.
• Neglecting equipment service contracts (typically 8–12% of equipment price annually) – reduces operating expenses, overestimating EBITDA margin by 5–8 percentage points.
• Using a single average cost per test ignoring the cost difference between low- and high-resolution typing – undervalues high-resolution services, distorting product-line profitability.
• Omitting the 12–18-month accreditation and validation phase before revenue – understates required initial funding, leading to a substantially longer cash break-even and potential liquidity gap.
• Ignoring reagent lot size and shelf-life dynamics – overstates gross margin during ramp-up because expired or partially used kits are not written off, inflating apparent profitability.